Neptune to Hold Conference Call
* Reuters is not responsible for the content in this press release.
LAVAL, Quebec, Oct. 11, 2011 (GLOBE NEWSWIRE) -- Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT) (TSX-V:NTB) will be holding a conference call and webcast on Thursday, October 13, 2011 at 4:30 pm ET. Topics to be discussed on the call include: -- Second quarter and year-to-date financial results, -- An update on commercial progress, -- Plans for production expansion, -- The recently announced Neptune-SKFC Chinese Joint Venture for Asian expansion. The webcast can be accessed in listen‐only mode free of charge, by clicking the link below: http://bit.ly/mRGMep To access the conference call by phone within Canada & the U.S. the toll‐free number is 1‐877-380-5664. Outside Canada and the U.S., dial 1‐631-813-4882. Callers should dial in five to 10 minutes prior to the scheduled start time and ask to be connected to the "Neptune call." Management will accept questions by telephone and e‐mail. Questions can be forwarded in advance or during the presentation to firstname.lastname@example.org. An archived recording of the webcast will be available on Neptune's website (www.neptunebiotech.com) two hours after the webcast. About Neptune Technologies & Bioressources Inc. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide. About Acasti Pharma Inc. Acasti Pharma (TSX-V:APO) is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by astaxanthin, a potent antioxidant. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets. About NeuroBioPharm Inc. NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners. "Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release." Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions. CONTACT: Neptune Contact: Neptune Technologies & Bioressources Inc. Andre Godin, CFO +1.450.687.2262 email@example.com www.neptunebiotech.com CEOcast Contact: Dan Schustack +1 212-732-4300 firstname.lastname@example.org www.ceocast.com Howard Group Contact: Dave Burwell (888) 221-0915 email@example.com www.howardgroupinc.com
- Japan PM makes offering to Yasukuni Shrine; China seizes ship
- South Korea president says conduct of ferry crew tantamount to murder |
- Deadly gun attack in eastern Ukraine shakes fragile Geneva accord |
- Australia sees 'regroup' on Malaysian plane search in a few days |
- At Mt. Gox bitcoin hub, 'geek' CEO sought both control and escape